Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer

References

• Ballester M, Canlorbe G, Cortez A, Gonin J, Laas E, Bendifallah S, et al. 2013. Histological and immunohistochemical profiles predict lymph node status in women with low-intermediate risk endometrial cancer. Gynecologic Oncology 130:457–462.
   PubMed Web of Science ®Google Scholar
• Banno K, Kisu I, Yanokura M, Tsuji K, Masuda K, Ueki A, et al. 2012. Biomarkers in endometrial cancer: possible clinical applications. Oncology Letters 3:1175–1180.
   PubMed Web of Science ®Google Scholar
• Bender D, Buekers T, Leslie KK. 2011. Hormones and receptors in endometrial cancer. Proceedings in Obstetrics and Gynecology 2:1.
   Google Scholar
• Bendifallah S, Canlorbe G, Collinet P, Arsène E, Huguet F, Coutant C, et al. 2015. Just how accurate are the major risk stratification systems for early-stage endometrial cancer? British Journal of Cancer 112:793–801.
   PubMed Web of Science ®Google Scholar
• Bokhman JV. 1983. Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology 15:10.
   PubMed Web of Science ®Google Scholar
• Bryś M, Szyłło K, Romanowicz-Makowska H, Dobrowolski Z, Masłowska I, Krajewska W. 2009. Expression of estrogen and progesterone receptor genes in endometrium, myometrium and vagina of postmenopausal women treated with estriol. Sao Paulo Medical Journal  =  Revista Paulista De medicina 127:128–133.
   PubMed Web of Science ®Google Scholar
• Ciarmela P, Islam MS, Reis FM, Gray PC, Bloise E, Petraglia F, et al. 2011. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Human Reproduction Update 17:772–790.
   PubMed Web of Science ®Google Scholar
• Di W-L, Lachelin GCL, McGarrigle HHG, Thomas NSB, Becker DL. 2001. Oestriol and oestradiol increase cell to cell communication and connexin43 protein expression in human myometrium. MHR: Basic Science of Reproductive Medicine 7:671–679.
   Google Scholar
• Dobrzycka B, Terlikowski SJ. 2010. Biomarkers as prognostic factors in endometrial cancer. Folia Histochemica Et Cytobiologica 48:319–322.
   PubMed Web of Science ®Google Scholar
• Dong P, Kaneuchi M, Konno Y, Watari H, Sudo S, Sakuragi N. 2013. Emerging therapeutic biomarkers in endometrial cancer. BioMed Research International 2013:130362.
   PubMed Web of Science ®Google Scholar
• Felix A, Weissfeld J, Edwards R, Linkov F. 2010. Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment. European Journal of Gynaecological Oncology 31:139–144.
   PubMed Web of Science ®Google Scholar
• Hanifi-Moghaddam P, Boers-Sijmons B, Klaassens AHA, van Wijk FH, Van Ijcken WF, Van der Spek P, et al. 2008. Difference in signalling between various hormone therapies in endometrium, myometrium and upper part of the vagina. Human Reproduction 23:298–305.
   PubMed Web of Science ®Google Scholar
• Hill GD, Moore AB, Kissling GE, Flagler ND, Ney E, Cline JM, Dixon D. 2011. Effects of hormonally active agents on steroid hormone receptor expression and cell proliferation in the myometrium of ovariectomized macaques. Toxicologic Pathology 39:508–515.
   PubMed Web of Science ®Google Scholar
• Huijgens ANJ, Mertens HJMM. 2013. Factors predicting recurrent endometrial cancer. Facts, Views & Vision in ObGyn 5:179–186.
   PubMedGoogle Scholar
• Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A. 2013. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecologic Oncology 130:463–469.
   PubMed Web of Science ®Google Scholar
• Jeon YT, Park IA, Kim YB, Kim JW, Park NH, Kang SB, et al. 2006. Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Letters 239:198–204.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Kurita T, Bulun SE. 2013. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocrine Reviews 34:130–162.
   PubMed Web of Science ®Google Scholar
• Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW. 2000. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Modern Pathology 13:379–388.
   PubMed Web of Science ®Google Scholar
• Li M, Zhao L, Shen D, Li X, Wang J, Wei L. 2014. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma. Chinese Medical Journal 127:1459–1463.
   PubMed Web of Science ®Google Scholar
• Maniketh I, Ravikumar G, Crasta JA, Prabhu R, Vallikad E. 2014. Estrogen and progesterone receptor expression in endometrioid endometrial carcinomas: a clinicopathological study. Middle East Journal of Cancer 5:67–73.
   Google Scholar
• Mozzachio K, Moore AB, Kissling GE, Dixon D. 2016. Immunoexpression of steroid hormone receptors and proliferation markers in uterine leiomyoma and normal myometrial tissues from the miniature pig, Sus scrofa. Toxicologic Pathology 44:450–457.
   PubMed Web of Science ®Google Scholar
• Sakaguchi H, Fujimoto J, Aoki I, Tamaya T. 2003. Expression of estrogen receptor alpha and beta in myometrium of premenopausal and postmenopausal women. Steroids 68:11–19.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2015. Cancer statistics, 2015. A Cancer Journal for Clinicians 65:5–29.
   PubMed Web of Science ®Google Scholar
• Singh M, Zaino RJ, Filiaci VJ, Leslie KK. 2007. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecologic Oncology 106:325–333.
   PubMed Web of Science ®Google Scholar
• Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P. 2001. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Archiv 438:470–477.
   PubMed Web of Science ®Google Scholar
• Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T, et al. 2010. Expression of ER, PR, and HER-2/neu in endometrial cancer: a clinicopathological study. Asian Pacific Journal of Cancer Prevention: APJCP 11:215–220.
   PubMedGoogle Scholar
• Tomica D, Ramić S, Danolić D, Knezević F, Kolak T, Balja MP, et al. 2014. A correlation between the expression of estrogen receptors and progesterone receptors in cancer cells and in the myometrium and prognostic factors in endometrial cancer. Collegium Antropologicum 38:129–134.
   PubMedGoogle Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2012. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 65:87.
   Web of Science ®Google Scholar
• Trovik J, Wik E, Werner HM, Krakstad C, Helland H, Vandenput I, et al. 2013. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer (Oxford, England: 1990) 49:3431–3441.
   PubMed Web of Science ®Google Scholar
• Welsh T, Johnson M, Yi L, Tan H, Rahman R, Merlino A, et al. 2012. Estrogen receptor (ER) expression and function in the pregnant human myometrium: estradiol via ERα activates ERK1/2 signalling in term myometrium. Journal of Endocrinology 212:227–238.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao D, Gong C, Zhang F, He J, Zhang W, et al. 2015. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology 13:208.
   PubMed Web of Science ®Google Scholar